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Obstetricians’ and gynecologists’ knowledge, education, and
practices regarding chronic hepatitis B in pregnancy
Bolin Niua, Dina Halegoua-De Marziob, Jonathan M. Fenkelb, Steven K. Herrineb
Thomas Jefferson University Hospital; Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

Abstract

Background In pregnant women with high viral loads, third-trimester initiation of antiviral agents
can reduce the risk of vertical transmission. We aimed to assess obstetricians’ and gynecologists’
(OB-GYN) knowledge and clinical practice when treating pregnant women with chronic hepatitis
B virus (HBV).
Methods All program directors (PDs) from 250 US OB-GYN residency programs were invited to
anonymously complete an 18-item questionnaire. Descriptive statistics were calculated and analyzed.
Results A total of 323 participants responded, including both PDs (n=51, response rate 21%) and
residents (n=272, response rate 11%). Responding PDs (62% university-based vs. 32% communitybased) came from various practice types. All PDs and 95.2% of residents reported screening for
chronic HBV in pregnant patients on the first prenatal visit. A majority of PDs (85.5%) and residents
(85%) correctly interpreted HBV serologies. Referral patterns showed that 66.7% of PDs and 65.5%
of residents refer to a specialist regardless of viral load. A minority of respondents (19.6% PDs and
12.6% residents) knew that third-trimester antiviral therapy is recommended for women with high
viral loads (>200,000 IU/mL). Few respondents had prescribed HBV antivirals (9.8% PDs and 6.0%
residents), with residents more commonly prescribing tenofovir and less frequently lamivudine.
Half the PDs believed trainees from their programs were comfortable managing HBV in pregnancy,
but only 41.8% of residents reported being comfortable managing pregnant patients with HBV.
Conclusion OB-GYNs report screening almost all pregnant patients for chronic HBV, though
significant gaps still exist in practitioner comfort and training regarding the management of HBV
during pregnancy.
Keywords Hepatitis B virus, pregnancy, obstetricians and gynecologists, survey, education,
practice
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HBV is a major risk factor for hepatocellular carcinoma,
leading to 50% of cases worldwide. There is an estimated
prevalence of 0.7-0.9% of chronic HBV among pregnant
women in the US, with >25,000 neonates at risk for chronic
infection annually [2,3].
Obstetricians and gynecologists (OB-GYNs) perform a
key role in the prevention of mother-to-child transmission
(MTCT). To provide optimal care of pregnant women who
are HBV carriers, OB-GYNs need appropriate knowledge,
education, and practice in the management of these
patients.
The Centers for Disease Control and Prevention and the
American College of OB-GYNs (ACOG) have both published
recommendations for screening for HBV among pregnant
women [5], calling for hepatitis B surface antigen (HBsAg) as
the initial serological testing for all pregnant women, followed
by hepatitis B e-antigen (HBeAg), HBV DNA viral load,
and alanine aminotransferase (ALT). If HBeAg is positive,
HBV DNA >20,000 IU/mL, or ALT ≥19 IU/L, then the
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Introduction
Between 800,000 and 1.4 million people in the United
States are infected with the hepatitis B virus (HBV) [1].
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patient should be referred to a specialist immediately during
pregnancy.
The 2016 American Association for the Study of Liver
Diseases (AASLD) guidelines suggest antiviral therapy to
reduce the risk of perinatal transmission of hepatitis B in
pregnant women with an HBV DNA level >200,000 IU/mL
(>1 million copies/mL) [4]. The 2016 Society for MaternalFetal Medicine consensus recommends third-trimester HBV
viral load testing and antiviral therapy over a greater range of
viral load (HBV DNA >1 million to 100 million copies/mL)
compared to the AASLD recommendation.
The current survey aimed to determine the knowledge,
education, and practices of OB-GYNs regarding HBV in
pregnant women. In addition, we determined referral patterns
and thresholds for OB-GYNs to treat patients with HBV.

Results
Characteristics of responders

A total of 323 participants from ACGME-accredited OBGYN residency programs across the US responded to the
survey (Table 1). The respondents included both PDs (n=51,
response rate of 21%) and residents (n=272, response rate of
11%). The responding resident cohort exhibited a diversity of
experience, with equal distribution across postgraduate years
(PGY) of training. Responding PDs came from varied practice
settings, including university-based (62%), community-based
(32%), and military-based (6%).
Practice patterns and peripartum management

Materials and methods
Participants

All program directors (PDs) from the 250 US OB-GYN
residency programs were invited via e-mail to complete an 18item online survey. E-mail addresses for PDs were obtained
from the American Medical Association FREIDA web site.
OB-GYN residents, contacted via e-mail by their PDs, were
also invited to participate.
Survey and administration

An 18-item survey was sent to PDs to obtain demographic
information and assess their knowledge, clinical practice, and
residency program education with regard to pregnant women
with chronic HBV. A slightly different 18-item survey was
written for trainees to obtain demographic information and
assess knowledge, clinical practice, and comfort level when
treating pregnant women with chronic HBV. The survey was
first piloted at several programs and adjusted from feedback.
Exemption status was obtained from Thomas Jefferson
University’s Institutional Review Board. Question responses
included agree, disagree, or unsure. Many questions allowed
for free-text comments. In January 2016, all participants were
contacted via e-mail with a cover letter describing the study
and a link to the Survey Monkey Website. Follow-up emails
were sent at 4 and 8 weeks after the initial e-mail to encourage
participation. Anonymized responses were stored in a database
for analysis.
Statistical analysis

Descriptive statistics, including means for continuous
variables and frequencies for categorical variables, were
calculated. The chi-squared test for significance was
employed.
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All PDs and 95.2% of residents reported screening for
chronic HBV in pregnant patients on the first prenatal visit.
Referral patterns showed that 66.7% of PDs and 65.5% of
residents referred to a specialist regardless of viral load.
A minority of respondents (19.6% PD, 12.6% residents)
knew that third-trimester antiviral therapy is recommended
for women with high viral loads (>1 million copies/mL or
200,000 IU/mL). Few respondents had prescribed antivirals
for HBV (9.8% PD, 6.0% residents). Residents more commonly
prescribed tenofovir (75%) and less frequently lamivudine
(16.7%). In contrast, more PDs prescribed lamivudine (60%)
and fewer tenofovir (40%). Furthermore, most PDs (98%) and
residents (83.1%) disagreed that HBV was an indication for
Cesarean section (C-section) (Table 2).
Education and interpretation of HBV serologies

Half of PDs believed residents from their programs were
comfortable in managing HBV in pregnancy, but only 41.8% of
residents reported being comfortable managing these patients
(Table 2). Only 23.5% of training programs have dedicated teaching
about HBV in pregnancy. With respect to years of training, the
percentage of residents who felt comfortable managing HBV
increased with post-graduate year: PGY 1 (22%), PGY 2 (28%),
PGY 3 (42%), and PGY 4 (69%) (Fig. 1). A majority of PDs and
residents interpreted HBV serologies correctly (Table 3).

Discussion
Because screening based on risk factors alone will miss
many cases of HBV, universal screening for HBV during
pregnancy at the first prenatal visit has been recommended
by the ACOG and the US Preventative Services Task Force for
many years [5]. In our study, all PDs and over 95% of residents
screened for HBV appropriately at the first prenatal visit.
Despite appropriate screening, significant gaps exist
in residents’ comfort and education in the management
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Table 1 Characteristics of responding PDs and residents
Responders’ characteristics

% PDs

% Residents

20.4

11.0

Male

37.3

10.9

Female

62.7

89.1

Community-based medical center

32

27.6

University-affiliated medical center

62

72.4

Group practice

4

0

Other

2

0

Urban

88.2

93

Rural

11.8

7

15.7

2.6

New England (CT, MA, ME, NH, RI, VT)

7.8

9.8

Mid-Atlantic (NJ, NY, PA)

15.7

25.8

East North Central (IL, IN, MI, OH, WI)

25.5

20.7

West North Central (IA, KS, MN, MO, ND, NE, SD)

9.8

11.3

Mountain (AZ, CO, ID, MT, NV, NM, UT, WY)

9.8

2.9

Pacific (AK, CA, HI, OR, WA)

7.8

8.7

South Atlantic (DE, DC, FL, GA, MD, NC, SC, VA, WV)

3.9

14.5

East South Central (AL, KY, MS, TN)

9.8

2.5

West South Central (AR, LA, OK, TX)

9.8

3.6

Overall
Survey response rate
Gender

Practice type

Practice setting

MFM
MFM specialty training
Geographical distribution

Trainee year
PGY 1

24.4

PGY 2

26.2

PGY 3

24.7

PGY 4 and beyond

24.7

PD, program director; MFM, maternal-fetal medicine; PGY, postgraduate year

of pregnant patients with HBV, though improvement is
seen as they progress through years of training. Even in
their last year of training, only 69% of PGY-4 residents
felt comfortable managing a pregnant patient with HBV.
This may be related to a lack of clinical exposure, with less
than half of residents reporting an adequate amount of
clinical exposure to HBV patients. In addition, less than a
quarter of programs offer a didactic session on HBV. Better
educational initiatives could potentially decrease MTCT
rates further.
Maternal infection with HBV is a major cause of
MTCT [6]. A recent study found that a maternal HBV DNA
level >1 million copies/mL at delivery is the most important
predictor of in utero MTCT and hepatitis B immune globulin

prophylaxis failure [7]. The newest guideline from the Society
for Maternal-Fetal Medicine recommends third-trimester
HBV viral load testing and antiviral therapy if viral load is
>6-8 log 10 (1 million to 100 million) copies/mL [8]. In 20122013, the European Association for the Study of the Liver and
the United Kingdom’s National Institute for Health and Care
Excellence have published similar guidelines, recommending
treatment in those with HBV viral load >6-7 log 10 (1 million
to 10 million) copies/mL [9,10].
With respect to the choice of antiviral therapy, the
American Association for the Study of Liver Diseases’
revised guidelines in 2009 for the treatment of chronic HBV
call for tenofovir and entecavir to be first-line agents, with
lamivudine no longer a first-line agent as there has been
Annals of Gastroenterology 30

4 B. Niu et al
100%
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Figure 1 Resident responses to “I feel comfortable managing pregnant patients with chronic hepatitis B” across post-graduate years
Table 2 Summary of selected survey responses from PDs and residents
Survey questions

Response

C-section is indicated in the setting of maternal HBV

There is a dedicated teaching session for managing hepatitis B in
pregnancy at my program

Trainees from my program are comfortable managing a
pregnant patient with hepatitis B

The patient population in my program provides adequate
clinical exposure for trainees with regard to HBV in pregnancy

PD response %
(n=51)

Resident response %
(n=275)

Chi-square
P-value

Agree

2.0

5.1

0.018

Disagree

98.0

83.1

Unsure

0.0

11.8

Agree

23.5

32.5

Disagree

70.6

41.0

Unsure

5.9

26.6

Agree

51.0

41.2

Disagree

29.4

28.7

Unsure

19.6

30.1

Agree

54.9

42.3

Disagree

41.2

37.5

Unsure

3.9

20.2

<0.001

0.265

0.017

PD, program director; HBV, hepatitis B virus; C-section, Cesarean section

concern about resistance [11]. Tenofovir has been shown to
be associated with no increase in congenital abnormalities
or differences in infant growth parameters at birth compared
to an untreated control group [12]. The newest guideline
from the Society for Maternal-Fetal Medicine recommends
tenofovir as a first-line agent in pregnant women who are
candidates for antiviral therapy [8]. Interestingly, a majority
of PDs who have prescribed antivirals selected lamivudine
as their agent of choice, while the majority of residents
Annals of Gastroenterology 30

selected tenofovir. It is likely that the new guidelines have
been disseminated faster to those who are currently in
training.
Perinatal HBV infection occurs when the infant comes into
contact with vaginal blood and secretions during delivery.
A Chinese systemic review that included 789 patients showed
a significant decrease in vertical transmission associated
with elective C-section (10.5%) compared to vaginal delivery
(28.0%) [13]. However, that review included many studies
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Table 3 Interpretations of HBV serologies
Type of HBV serology

% PD correct

% Resident
correct

Chronic hepatitis B infection

94

86

Prior infection with hepatitis
B, now resolved

80

78.8

Immune to hepatitis B from
vaccination

82.4

90.1

PD, program director; HBV, hepatitis B virus

Summary Box
What is already known:

• Mother-to-child transmission of hepatitis B virus
(HBV) occurs when maternal HBV viral load is
higher than 1,000,000 copies/mL
• Third-trimester initiation of antiviral agents
reduces the risk of vertical transmission
What the new findings are:

• Our survey of all Obstetricians’ and Gynecologists’
(OB-GYN) residency programs in the United
States shows almost all OB-GYNs screen pregnant
patients for HBV
• A minority of OB-GYN respondents knew that
third trimester antivirals are recommended for
women with high viral loads
• Less than half of residents report that they are
comfortable managing patients with HBV
• Less than a quarter of residency programs have
dedicated teaching about HBV in pregnancy

that did not report maternal HBV DNA viral load. Currently,
the OB-GYN literature does not support chronic HBV as
an indication for C-section [8]. The majority of PDs and
residents in our survey reported similar opinions regarding
C-section.
Although we surveyed PDs and residents in the entire
US, the major limitations of our study include the recall bias
inherent in survey studies and the slightly low response rates.
We elected to survey PDs as representative of physicians in
practice. However, this may not be accurate, as PDs are perhaps
more knowledgeable about changing guidelines than are their
non-teaching colleagues.

Overall, despite excellent self-reported screening for
hepatitis B in pregnant women, OB-GYN knowledge and
education regarding management, especially in patients with
higher viral loads during the third trimester, is still lacking.
Improvement in education and dissemination of guidelines
can further decrease vertical transmission in this vulnerable
population.

References
1. Masters BR. Mandell, Douglas, and Bennett’s Principles and
Practice of Infectious Diseases, Eighth Edition (2015) Eds: John E.
Bennett, Raphael Dolin, Martin J. Blaser. ISBN: 13-978-1-45574801-3, Elsevier Saunders. Graefes Arch Clin Exp Ophthalmol
2016;254:2285-2287.
2. Kubo A, Shlager L, Marks AR, et al. Prevention of vertical
transmission of hepatitis B: an observational study. Ann Intern Med
2014;160:828-835.
3. Din ES, Wasley A, Jacques-Carroll L, Sirotkin B, Wang S. Estimating
the number of births to hepatitis B virus-infected women in 22
states, 2006. Pediatr Infect Dis J 2011;30:575-579.
4. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM,
Murad MH; American Association for the Study of Liver Diseases.
AASLD guidelines for treatment of chronic hepatitis B. Hepatology
2016;63:261-283.
5. American College of Obstetricians and Gynecologists. ACOG
Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet
Gynecol 2007;110:941-956.
6. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of
perinatal hepatitis B virus exposure is dependent on maternal virus
load. J Infect Dis 1994;170:1418-1423.
7. Pan CQ, Duan ZP, Bhamidimarri KR, et al. An algorithm for risk
assessment and intervention of mother to child transmission of
hepatitis B virus. Clin Gastroenterol Hepatol 2012;10:452-459.
8. Dionne-Odom J, Tita AT, Silverman NS; Society for MaternalFetal Medicine (SMFM). #38: Hepatitis B in pregnancy screening,
treatment, and prevention of vertical transmission. Am J Obstet
Gynecol 2016;214:6-14.
9. European Association For The Study Of The Liver. EASL clinical
practice guidelines: Management of chronic hepatitis B virus
infection. J Hepatol 2012;57:167-185.
10. National Clinical Guideline Centre (UK). Hepatitis B (Chronic):
Diagnosis and management of chronic hepatitis B in children,
young people and adults [Internet]. London: National Institute
for Health and Care Excellence (UK); 2013 [cited 2016 Dec 16].
Available from: http://www.ncbi.nlm.nih.gov/books/NBK254250
11. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology
2009;50:661-662.
12. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of
tenofovir disoproxil fumarate in pregnancy to prevent perinatal
transmission of hepatitis B virus. J Hepatol 2014;61:502-507.
13. Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section
versus vaginal delivery for preventing mother to child transmission
of hepatitis B virus—a systematic review. Virol J 2008;5:100.

Annals of Gastroenterology 30

